Head-To-Head Survey: Cellectar Biosciences (CLRB) vs. Its Peers

Cellectar Biosciences (NASDAQ: CLRB) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Cellectar Biosciences to similar businesses based on the strength of its valuation, dividends, risk, analyst recommendations, earnings, profitability and institutional ownership.


This table compares Cellectar Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectar Biosciences N/A -97.36% -83.40%
Cellectar Biosciences Competitors -2,859.89% -68.22% -9.44%

Institutional and Insider Ownership

2.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 10.2% of Cellectar Biosciences shares are held by insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Cellectar Biosciences has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Cellectar Biosciences’ peers have a beta of 0.90, suggesting that their average share price is 10% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cellectar Biosciences and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences 0 0 2 0 3.00
Cellectar Biosciences Competitors 844 3780 6809 185 2.55

Cellectar Biosciences presently has a consensus price target of $2.70, indicating a potential upside of 77.63%. As a group, “Pharmaceuticals” companies have a potential upside of 23.76%. Given Cellectar Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectar Biosciences is more favorable than its peers.

Earnings & Valuation

This table compares Cellectar Biosciences and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Cellectar Biosciences N/A -$10.78 million -1.23
Cellectar Biosciences Competitors $8.08 billion $2.63 billion 0.05

Cellectar Biosciences’ peers have higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Cellectar Biosciences peers beat Cellectar Biosciences on 7 of the 12 factors compared.

About Cellectar Biosciences

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

What are top analysts saying about Cellectar Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cellectar Biosciences Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit